Taken together, we investigated the clinicopathologically significant oncogenic role of IL13Rα2 in 229 RCC patients and the high expression of IL13Rα2 was significantly associated with cancer-specific survival and relapse-free survival in univariate and multivariate analysis. This evidence concerns the gene IL13RA2 and renal cell carcinoma.